This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (89)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Pilot Study

Rudolph H. Ehrensing, MD; Abba J. Kastin, MD

Arch Gen Psychiatry. 1974;30(1):63-65.

Abstract
The melanocyte-stimulating hormone (MSH)-release inhibiting hormone, prolyl-leucyl-glycinamide (MRIH-I), is a hypothalamic hormone active in animal systems used as models of depression.

In a double-blind, clinical trial, four of five patients with mental depression, who received 60 mg of MRIH-I for each of six consecutive days, experienced marked improvement for their symptoms within. two to three days.

The preliminary nature of these findings, however, is emphasized by the improvement in two of four patients receiving a placebo and only two of five patients receiving 150 mg of MRIH-I.

Author Affiliations
New Orleans

From the Department of Psychiatry, Louisiana State University School of Medicine and Endocrinology Section of the Medical Service, Veterans Administration Hospital, and the Department of Medicine, Tulane University School of Medicine, New Orleans.

Footnotes
Accepted for publication Oct 9, 1973.

Reprint requests to the Department of Psychiatry and Biobehavioral Sciences, Louisiana State University Medical Center, 1542 Tulane Ave, New Orleans, LA 70112 (Dr. Ehrensing).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?